Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.68 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.68 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.61 |
| ▸ | ACE | P12821 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9138110 | 0.89 | DPP8 (0.66) | DPP8DPP7NOTUMACEKDM4E | |
| SCHEMBL13918276 | 0.89 | NOTUM (0.55) | DPP8DPP7NOTUMACEKDM4E | |
| SCHEMBL5870235 | 0.85 | DPP8 (0.57) | DPP8DPP7NOTUMACEKDM4E | |
| SCHEMBL5870531 | 0.85 | DPP8 (0.57) | DPP8DPP7NOTUMACEKDM4E | |
| SCHEMBL3103829 | 0.84 | DPP8 (0.68) | DPP8DPP7NOTUMACEKDM4E | |
| SCHEMBL13487186 | 0.82 | NOTUM (0.67) | DPP8DPP7NOTUMACEKDM4E | |
| SCHEMBL303340 | 0.82 | NOTUM (0.67) | DPP8DPP7NOTUMACEKDM4E | |
| SCHEMBL5870438 | 0.82 | DPP8 (0.54) | DPP8DPP7NOTUMACEKDM4E | |
| SCHEMBL4612404 | 0.81 | ALDH1A1 (0.60) | DPP8DPP7NOTUMACEKDM4E | |
| SCHEMBL6972682 | 0.81 | NR1H2 (0.51) | DPP8DPP7NOTUMACEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-7511062-B2 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (IN) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | DPP8 703/4885DPP7 362/4885NOTUM 2412/4885 |
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | DPP8 870/4885DPP7 797/4885NOTUM 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.